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Long-term enalapril and verapamil in rats with reduced renal mass.
The effect of long-term treatment with either enalapril or high dose
verapamil on survival, proteinuria, blood pressure and renal morphol-
ogy was studied in female Wistar rats with markedly reduced renal
mass. Four weeks were allowed for remnant kidney hypertrophy before
determining the response to renal ablation of individual animals regard-
ing proteinuna and hypertension. At this time, five groups of 18 rats
were formed with equal levels of proteinuria and hypertension. Groups
El and E2 were treated with enalapril, groups VI and V2 with
verapamil, and one group served as control. The daily food allowance
was 14 g/rat of a standard rat diet, containing 30% protein and 100 mmol
NaClIkg food in groups El and VI. NaCI content was reduced to 20
mmol/kg food in groups E2, V2 and control. The drugs were added to
the drinking water, enalapril at a dose of 0.1 glliter, verapamil at 0.5 to
0.7 g/liter. Drug intake thus amounted to 10 to 25 mg/kg for enalapril and
50 to 140 mg/kg for verapamil, Treatment was continued for 15 weeks.
Three of the 18 control rats did not survive up to 15 weeks. Mortality
was lower in the enalapril treated groups with a single nonsurvivor in
group El. In contrast, mortality was higher in the verapamil treated
animals with seven nonsurvivors in group VI and eight in group V2.
Blood pressure control was excellent in both enalapril treated groups,
and proteinuria decreased in most animals of group El and all of group
E2. Glomerulosclerosis did not develop in the majority of the enalapril
treated animals. Despite the high dose, verapamil barely lowered blood
pressure. However, proteinuria rose markedly in response to verapamil
causing hypoalbuminemia and hyperlipidemia. Increased proteinuria
was associated with a higher percentage of sclerotic glomeruli in the
verapamil treated groups. Kidney weight was highly significantly cor-
related with proteinuria. Kidney enlargement thus appeared to be
caused by tubular dilatation and filling with proteinaceous casts depend-
ing on the level of proteinuria. The favorable effect of enalapril on
remnant kidney function and morphology was confirmed. In contrast,
verapamil worsened proteinuria, tended to promote glomerulosclerosis
and shortened survival of rats with reduced renal mass.
After extensive renal ablation, the remaining normal renal
tissue undergoes functional and morphological hypertrophy. In
animal models this process is associated with proteinuria and
hypertension [1, 2] followed by progressive glomerulosclerosis,
and ultimately leading to renal destruction and death in uremia.
This deleterious response to renal ablation can be delayed by
feeding a low protein diet, which is thought to act through
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decreasing intraglomerular pressure and nephron perfusion
[3—5]. Although a low protein diet decreases proteinuria, it has
no effect on systemic hypertension in the rat renal ablation
model [3, 5]. Systemic hypertension by itself may cause or
worsen progressive glomerular injury as shown in a variety of
experimental circumstances such as "post-salt" hypertension
in rats [6], the unclamped Goldblatt kidney [7, 8] and DOCA-
salt hypertension [8]. Protection from systemic hypertension by
clamping one renal artery in DOCA-salt hypertension pre-
vented glomerular injury in the clamped kidney [8]. Further-
more, systemic hypertension worsens progressive glomerular
injury of experimental glomerulonephritis in salt-sensitive DahI
S rats [9], and antihypertensive therapy may reduce glomerular
injury, as shown recently in rats with experimental glomerulo-
nephritis [10, 11], diabetes mellitus [12], and after renal ablation
[13, 14]. The purpose of the present study was to compare an
angiotensin converting enzyme inhibitor to a calcium antagonist
in their effects on hypertension, proteinuria and progressive
glomerulosclerosis in rats with hypertrophied remnant kidneys
on a moderately high protein intake.
Methods
Renal ablation was performed in a total of 125 female Wistar
rats over a five week period. Once weekly a group of 25 animals
weighing 120 g were anesthetized with Nembutal 40 mg/kg body
wt i.p. The left renal pedicle was carefully dissected through a
midline abdominal incision. Two to three upper branches of the
left renal artery were tied off using prolene 5-0 suture. One
week later, the right kidney was removed after ligating the right
renal pedicle from a flank incision under ether anesthesia.
Another four weeks later, the rats were placed in individual
metabolic cages for two days. The 24 hour urine of the second
day was used to determine proteinuria and creatinine excretion.
Blood was obtained from the cut end of the tail. Arterial blood
pressure was measured by tail plethysmography in the awake
rat. Since the range of the plethysmograph used did not exceed
200 mm Hg, pressures over 200 were recorded as "205" mm Hg
for calculation of Spearman rank correlation coefficients. The
animals were then allocated to five treatment groups with
similar degrees of proteinuria and hypertension. Of every 25
rats that underwent renal ablation simultaneously, a few ani-
mals died immediately after surgery or developed uremic symp-
toms soon thereafter and were excluded. We thus obtained five
subgroups of three or four animals each, which were housed in
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Table 1. Renal function and systolic blood pressure before starting treatment with enalapril (E) or verapamil (V)
Group
Control
N = 18
El
N = 18
E2
N = 18
VI
N = 18
V2
N = 18
1Cr tmo1e/liter
mean SEM
Cr mi/mm 100g body wt
mean SEM
Proteinuria mg/mol Cr
mean SEM
Median systolic BP mm Hg(N rats with BP  200 mm Hg)
72 4
0.32 0.02
2.16 0.30
185
(7)
73 5
0.30 0.02
2.14 0.30
190
(6)
73 4
0.31 0.02
2.16 0.33
185
(6)
68 5
0.32 0.02
2.03 0.26
193
(7)
73 3
0.29 0.01
2.06 0.28
180
(7)
group cages with good access to food and with tap water ad
libjtum. Over five weeks a total of 18 rats were started in each
experimental group (groups El and E2 on enalapril, groups Vi
and V2 on verapamil) and the control group. Enalapril and
verapamil were added to the drinking water, enalapril at a
concentration of 0.1 g/liter, and verapamil at a concentration of
0.5 g/liter during the first week and 0.7 g/Iiter thereafter. Rats on
enalapril drank between 10 and 25 ml/i00 g body wt and were
thus receiving 10 to 25 mg/kg body wt of the drug. Fluid intake
varied between 10 and 20 ml/l00 g body wt in the verapamil
treated groups, resulting in a drug intake of 50 to 140 mg/kg
body wt. The animals were offered 14 glrat/day of a standard
ground rat diet (Klingentalmuhle AG, Basel, Switzerland) con-
taining 30% protein (casein IA) and 100 mmol NaCI per kg food
before separation into the five groups. Groups El and Vl
remained on this diet, whereas salt intake was restricted in
groups E2, V2 and the control group by reducing dietary salt
content to 20 mmol/kg food. Left-over food was weighed.
Every five weeks, the animals were placed into the metabolic
cages for two days to determine proteinuria and creatinine
clearance followed by phlethysmographic measurement of
blood pressure in the afternoon of the third day. Rats that
looked sick were killed with ether, exsanguinated for determi-
nation of plasma creatinine, and the kidneys removed for
histological examination. After 15 weeks all the surviving rats
were sacrificed, and hearts and kidney remnants weighed after
exsanguination. A Beckman creatinine analyzer was used to
measure creatinine in blood and urine, and the central hospital
laboratories' multichannel Hitachi analyzer for determining
plasma electrolytes and lipids. Plasma albumin was measured
colorimetrically with bromcresol green [151. Urinary protein
content was determined by tannic acid precipitation with Fe3 +
colorimetry as described by Yatzidis [161. For histological
examination, the kidneys were fixed in phosphate-buffered 4%
formalin. Three m sections were stained with hematoxylin
eosin, periodic acid/Schiff, periodic acid/silver methenamine
and chromotrope anilin-blue. Fifty glomeruli were examined in
each kidney for the presence or absence of segmental or global
glomerular sclerosis, and 10 to 20 sections of arterioles or
interlobular arteries for exsudative or proliferative hypertensive
vasculopathy. Care was taken to evaluate renal histology in
intact hypertrophied parts of the remnant kidneys outside of
scarred regions close to infarcted areas. Mean glomerular
diameter was determined for each kidney by measuring the
diameter of 10 nonsclerosed glomeruli above the papilla half-
way between the corticomedullary junction and the cortical
surface. The pathologist (M.J. Mihatsch) evaluated renal his-
tology without knowledge of the treatment the rats had re-
ceived.
Results are expressed as means SEM, or the medians are
given with the range. Mann-Whitney's U-test, Wilcoxon's
paired test, Fisher's exact test and the Spearman rank correla-
tion were used as appropriate for statistical evaluation.
Results
Our technique of tying off two to three upper branches of the
left renal artery caused infarction of about half to two-thirds of
that kidney. Together with the removal of the right kidney,
renal mass was reduced by at least 4/5. Most animals survived
the procedure and thereafter gained weight normally. At the
time of forming the four experimental and the control groups,
mean body weight had risen to 180 g. Mean values for renal
function and proteinuria as well as median blood pressure
before commencing the different regimens are shown in Table 1.
Proteinuria is expressed in mg per jmol urinary creatinine to
minimize variability due to collection errors. The range of
proteinuria was extremely wide but again quite similar between
groups (Fig. 1). The extremes of 0.5 and 5 mg/imol creatinine
corresponded to daily protein excretion rates of 15 and 150
mg/l00 g rat/day. There was a highly significant correlation
between proteinuria and blood pressure (Spearman r = 0.68, P
<0.00001).
For practical reasons drugs were administered with the
drinking water. The approximate daily drug intake was between
10 and 25 mg/kg enalapril and 50 to 140 mg/kg verapamil.
Animals of groups El, E2 and control consumed their daily
food allowance of 14 g almost always without any left-overs. A
few of the verapamil treated animals were eating less, which led
to slightly lower mean body weight at 10 and 15 weeks in those
surviving the whole experimental period.
Survival curves are shown in Figure 2. A single animal had to
be killed in group El at day 64, while all the 35 other rats on
enalapril were surviving up to sacrifice at 15 weeks. Survival
was intermediate in the control group where one rat died
spontaneously and two had to be killed after 33 to 59 days. For
the two verapamil groups mortality was significantly higher
than control (42% vs. 16%, Fisher's exact test, P < 0.05). Seven
rats of group V 1 and eight of group V2 did not survive, with two
animals in each group dying spontaneously and the others
having to be killed mostly between 30 and 100 days after being
started on verapamil.
All but three of these 15 nonsurvivors had baseline protein-
uria and blood pressure above the median values of the 90 rats
studied. Higher than median initial proteinuria worsened in all
5.0
I
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Fig. 1. Proteinuria of individual animals at 0, 5, 10 and 15 weeks after starting treatment with enalapril (E) or verapamil (V) compared to control.
+ denotes nonsurviving rat.
kidney remnants available for histological examination (serum
creatinine 190, 350 and 530 imo1Iliter at sacrifice).
For rats surviving the entire experimental period, results are
summarized in Tables 2 and 3. Enalapril significantly lowered
arterial blood pressure in groups El and E2. In contrast, blood
pressure remained elevated in groups Vl and V2 despite the
relatively high dose of verapamil. Poor control of blood pres-
sure was substantiated by a higher heart weight in group Vi,
while both enalapnl groups had significantly smaller hearts than
control (Table 3). No statistically significant differences be-
tween groups were obtained regarding creatinine clearance, but
plasma creatinines were significantly lower at five weeks in the
verapamil treated groups, and tended to be lower than control
at five and 10 weeks in the enalapril treated groups (Table 2). In
contrast, proteinuria was influenced markedly by the two drugs
and in opposite direction (Fig. 1). Enalapril decreased protein-
uria at five weeks in all but four of the 36 rats. Only three rats
of group El with marked baseline proteinuria excreted rising
amounts of urinary protein, while proteinuria continued to
decrease or remained at the same low level in the other 15 group
El rats as well as in the entire salt-restricted group E2. Just the
opposite occurred in the verapamil treated groups, where
proteinuria rose continuously in all but one rat. In the control
group proteinuria continued to increase in nine, stabilized in
five and decreased in four rats. The sequelae of proteinuria, that
is, hypoalbuminemia, hypercholesterolemia and hypertriglycer-
idemia, were conspicuous in the control group and significantly
more pronounced in the verapamil treated groups when com-
pared to groups El and E2 (Table 3).
Remnant kidney size and histology differed between groups
after 15 weeks of treatment (Table 4). Mean kidney wet weight
of enalapril treated rats was comparable to control. In contrast,
the majority of the verapamil treated rats had much larger
kidneys at sacrifice. Kidney weight correlated well with pro-
teinuria in all groups except group E2, where all animals had
Control
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Fig. 2. Survival curve showing higher mortality for 36 rats on vera-
pamil (groups VI + V2) and lower mortality for 36 rats on enalapril
(groups El + E2) as compared to the 18 control rats.
nonsurvivors irrespective of treatment group, and reached
values between 5 and 20 mgI.tmol creatinine at 5 or 10 weeks
(Fig. 1). Plasma creatinine concentration at time of death or one
day earlier averaged 202 37 iimol/liter in 13 nonsurvivors of
the verapamil treated groups (no plasma available in two
animals) and ranged between 120 and 210 tmo1Iliter in the three
nonsurvivors in the control group. Renal histology of these
nonsurviving rats differed little between groups and disclosed
marked glomerulosclerosis involving 30 to 90% of glomeruli.
Only in the very early deaths in the verapamil treated groups
was the degree of glomerulosclerosis inferior, with 20% or
fewer glomeruli showing segmental sclerosis in three of four
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Table 2. Renal function, proteinuria and systolic blood pressure in surviving rats before (week 0) and at 5 to 15 weeks of
enalapril (E) and verapamil (V)
treatment with
Control El E2 Vl V2
Week N = 15 N = 17 N = 18 N = 11 N 10
Pc i.unole/liter 0 73 4 72 5 73 4 62 5
mean SEM 5 81 4 74 3 69 3C 60
65 3
61 4
10 81±3 71±4c 67±3e 80±7 74±3
15 91±4 794" 82±5 84±8 93±12
Ccr mi/mm 100 g body wt 0 0.31 0.02 0.31 0.02 0.31 0.02 0.35 0.03 0.32 0.02
mean SEM 5 0.25 0.01 0.26 0.01 0.26 0.02 0.32 0.01 0.29 0.02
10 0.24 0.01 0.25 0.01 0.25 0.01 0.23 0.02 0.24 0.02
15 0.22 0.01 0.23 0.01 0.21 0.01 0.22 0.02 0.20 0.02
Proteinuria mg//.unoi Cr 0 1,56 1.61 2.08 1.18 1.36
median (range) (0.51—3.72) (0.72—3.78) (0.70—5.82) (0.57—3.02)
5 1.94 0.68C 0.59 362c,h
(0.55—2. 17)
2.98C1
(0.39—4.21) (0.33—5.20) (0.38—1.21) (0.62—10.50)
10 2.40 o.soe o44e 756C.h
(1.66—9.47)
523e,h
(0.37—7.58) (0.18—6.69) (0.23—0.86) (0.48—16.50) (2.83—15.90)
15 1.94 0.50C 0.43 8.8l" 658c,h
(0.31—11.30) (0.21—11.50) (0,24—0.96) (0.40—16.40) (2.66—19.50)
Systolic BP mm Hg 0 175 190 185 160 173
median (range) (100—>200) (135—>200) (I 10—>200) (145—>200)
5 180 140g iIS 165 (140—>200)168"
(l40—>200) (100—170) (105—150) (125—>200) (145—>200)
10 180 125 180" 165"
(145—>200) (100—155) (100—145) (145—>200) (105—180)
15 175 I20 1l0 l58" 158b,h
(125—>200) (105—180) (100—130) (145—>200) (145—185)
Salt intake was restricted to 20 mmol NaCl/kg food in groups E2, V2 and control.N_ 9bN 8
P (Mann-Whitney's U-test) vs. control El vs. VI, E2 vs. V2 s"' e.f <0.01,
Table 3. Body weight, wet heart weight, plasma albumin and plasma lipids of surviving rats at sacrifice
Control El E2 VI V2
N=15 N=17 N=l8 N=l1 N=lO
Body wt g 228 5 225 4 224 4 201 8 210 c,d
Heart wt 0.33 0.06 0.25 0.24 0.02w 0.40 0.08cI 0.37 0.07"
g/100 g body wt
Palbumin 33 1 36 IC 37 IC 31 l 31
gluier
P cholesterol 2.6 0.4 1.8 0.3 1.5 0.lC 3.5 9" 4.0 07b.c.h
.unoi/liter
P triglycerides 0.9 0.2 0.7 0.2 0.5 0.1 1.8 07b 2.0 0.7"
All values are mean SEM
= 8bN7
P (Mann-Whitney's U-test) vs. control El vs. Vl, E2 vs. V2 C.d <0.05, Cf <0.01, " <0.001
little proteinuria and low kidney weight. Systolic blood pressure
generally did not correlate with kidney weight.
Histologic examination disclosed marked differences be-
tween small and large kidneys. The latter showed a great
number of dilated tubules which contained huge proteinaceous
casts. This was particularly conspicuous in the verapamil
treated groups and typical for animals with the heaviest pro-
teinuria. The difference in kidney weight appeared to be ac-
counted for entirely by proteinaceous casts within dilated
tubules (Fig. 3). Typical hypertensive arteriolopathy occurred
rarely and was limited to a few vessels of kidneys from each
group, although minor vascular alterations were widespread.
Fifty glomeruli were examined in each kidney for the pres-
ence or absence of sclerosis. The percentage of glomeruli with
segmental or global sclerosis was highest in groups Vi and V2
(P < 0.05 for Vi and V2 pooled vs. control, Mann-Whitney's
U-test) and lowest in the salt-restricted group E2 (P < 0.001 vs.
control; Fig. 4). Mean systolic blood pressure correlated with
glomerulosclerosis in groups El and Vi but not in groups E2
and V2. Pi-oteinuria showed an excellent correlation with
glomerulosclerosis in all groups except group E2, where both
glomerulosclerosis and proteinuria were minimal in all animals
(Table 4).
Nonsclerosed glomeruli tended to be smaller in the enalapril
treated rats and larger in the verapamil treated groups (Table 4).
However, as shown in Figure 5, there was a definite relation
between the glomerular diameters and the percentage of scle-
rosed glomeruli, which did not differ between the experimental
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Table 4. Kidney wet weight and histological findings in surviving rats
Control El E2 VI V2
N—iS N=17 N=18 N=11 N=I0
Kidney weight Median 0.42 0.41 0.39 0.93'Ig 073d.g
g/100 g body wt range 0.33—0.96 0.31 —0.65 0.31 —0.49 0.44 —1.42 0.52 —1.98
Correlation with
systolic BP r 0.49 0.47 0.15 0.60 0.20
P <0.05 NS NS NS NS
Proteinuria r 0.78 0.85 0.06 0.83 0.78
P <0.002 <0.002 NS <0.01 <0.02
Glomerulosclerosis
Percent glomeruli mean SEM 20.0 6.5 9.4 4.7 1.2 O.6 34.9 8.0aC 31.6 578
Correlation with
systolic BP r 0.69 0.65 0.36 0.75 0.21
P <0.01 <0.01 NS <0.02 NS
proteinuria r 0.83 0.77 0.22 0.87 0.63P <0.002 <0.002 NS <0.01 <0.05
Glomerular diameter
.un mean SEM 131 4 130 5 117 5b 142 6 150 8b.e
Spearman rank correlation was determined with the mean values of systolic blood pressure at 5, 10 and 15 weeks with proteinuria immediately
before sacrifice.
a N = 10
P (Mann-Whitney's U-test) vs. control El vs. VI, E2 vs. V2 b.c <0.05, d.c <0.01, <0.001
Fig. 3. Whole kidney sections of enalapril treated animal with protein-
uria of 0.35 mg/p.mol creatinine (left) compared to verapamil treated
animal with proteinuria of 3.1 mgI j.smol creatinine (right) at sacrifice
after 15 weeks of treatment. Note enlargement due to dilated tubular
structures with darkly staining proteinaceous casts in verapamil kidney
(magnification 4 times, chromotrope anilin blue stain).
groups. Kidneys with little glomerulosclerosis had the same
glomerular diameters in all groups, which appeared to be
affected neither by treatment with enalapril nor verapamil.
Thus, the progressive loss of viable glomeruli by sclerosis was
associated with increasing size of nonsclerosed glomeruli irre-
spective of treatment.
Discussion
This study aimed at examining the effect of commonly used
antihypertensive drugs in a model of markedly reduced renal
mass with fully developed hypertrophy of the kidney remnant
associated with variable degrees of hypertension and protein-
uria. A rather high dietary protein content of 30% was chosen to
assure rapid hypertrophy and hyperfiltration. The amount of
food offered to the animals was restricted to 14 glday to
minimize differences in food intake between groups and to
achieve identical protein loads. The response to renal ablation
varied considerably. Proteinuria was minimal in some and 10
times higher—clearly within the nephrotic range—in other
animals. Systolic blood pressure was normal or barely elevated
in a few rats and exceeded 200 mm Hg in many others. Since
previous studies had shown that the level of proteinuria was the
most important prognostic factor regarding survival [17], we
took great care to evenly allocate rats with similar amounts of
proteinuria to the five experimental groups. Since proteinuria
correlated well with systolic blood pressure, an even distribu-
tion of blood pressures was also achieved among the five
groups.
In the control group where salt intake was restricted to 20
mmol NaCl/kg food, proteinuna decreased or stabilized in half
and continued to increase in the other half of the rats, three of
which did not survive the 15 week experimental period. Com-
pared to this control group, we obtained excellent therapeutic
results by enalapril and the opposite, worsening of proteinuna
and increased mortality by verapamil.
For practical reasons, enalapril and verapamil were adminis-
tered in the drinking water. Unpublished pilot studies in our
laboratory had shown that enalapnl in a dose of 0.1 g/liter
drinking water completely blocks serum converting enzyme
levels in female Wistar rats. Anderson et al [14] reported that
even half that dose was effective in lowering blood pressure and
decreasing proteinuna and glomerulosclerosis in Munich-
Wistar rats when administered immediately after renal ablation.
These elegant studies furthermore demonstrated that convert-
ing enzyme inhibition prevented the rise in glomerular capillary
pressure which occurs in rats with renal ablation fed abundant
amounts of protein. The present study demonstrates a benefi-
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in our rats as well and thereby lowered proteinuria and delayed
or prevented progressive glomerulosclerosis. Converting en-
zyme inhibition proved particularly successful in reducing
proteinuria and glomerulosclerosis when combined with salt
restriction (group E2). Salt restriction enhanced the antihyper-
tensive action of enalapril and may have caused a further
reduction in glomerular capillary pressure.
Verapamil, like other calcium channel blockers, has excellent
antihypertensive properties when given by gavage in doses of
100 to 150 mg/kg daily [19] or added at a concentration of 0.9
g/liter to the drinking water [20] in spontaneously hypertensive
rats. The antihypertensive effect is mediated through decreased
smooth muscle tone of resistance vessels [211. Hypertensive
arteriolopathy and calcium uptake by arterial smooth muscle
cells are effectively prevented by this and a wide variety of
other calcium antagonists [22]. Recently low dose verapamil
(0.1 mg/kg twice daily i.m. or s.c.) has been found to ameliorate
uremic calcinosis [231 and to slow progressive renal failure [24]
in rats with subtotal nephrectomy. At this dose, blood pressure
was slightly lowered [25] or unchanged [24]. In view of these
reported benefits the finding of increased mortality and glomer-
uloscierosis in the verapamil treated groups is certainty surpris-
ing and difficult to understand. However, there are at least two
important differences between this and earlier studies, namely
the point in time of starting verapamil and the dosage and route
of administration of the drug. Harris et a! [24] started treatment
60 70 80 with verapamil immediately after renal ablation, whereas five
weeks were allowed for undisturbed hypertrophy of the kidney
remnants before administering verapamil in the present study.
At the low dose of 0.1 mg/kg injected twice daily by Harris eta!,
the elevated blood pressure was not affected at all, Although we
intended to administer 100 to 150 mg/kg oral verapamil daily,
which is sufficient to normalize blood pressure in spontaneously
hypertensive rats [19], many of the group Vl and V2 rats drank
less than anticipated and thus had a lower verapamil intake
which ranged between 40 and 100 mg/kg in many instances.
Hence, the slight reduction of systemic blood pressure mea-
sured in the afternoon in some animals did not reach statistical
significance for the group as a whole. We can only speculate
that blood pressure might have been lower during the night
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Fig. 5. Mean glomerular diameter of nonsclerosed glomeruli of indi-
vidual kidney remnants at sacrifice after /5 weeks of treatment with
enalapril (Q El, U £2) or verapamil ( Vi, A V2) compared to control
(&. The regression lines of the enalapril treated groups (II), of the
vcrapamil groups (L) and of the control group (•) have a similar slope.
cia! effect of converting enzyme inhibition started five weeks
after reducing renal mass. This is consistent with the findings of
Meyer et a! [18], who reported a reduction of elevated glomer-
ular capillary pressure and proteinuria when enalapril was
begun eight weeks after renal ablation. We may assume,
therefore, that enalapril reduced glomerular capillary pressure
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when the rats were active and, therefore, were receiving the
better part of their daily verapamil dose dissolved in the
drinking water. The bioavailability of verapamil after oral
administration is low, mainly due to removal of over 80% of the
drug during the first pass through the liver (unpublished infor-
mation supplied by Knoll AG, Ludwigshafen, FRG). Assuming
that only 5% of the administered drug reached the systemic
circulation, the regimen of the present study was still supplying
10 to 40 times more verapamil than the one by Harris et a!. It is
therefore likely that the large dose used in the present study was
hemodynamically effective, and caused decreased afferent renal
arteriolar resistance as deduced from increased stop flow pres-
sure and renal blood flow during intravenous infusion of vera-
pamil in our remnant kidney model [261. Subcutaneous vera-
pamil twice 0.1 mg/kg daily was recently found not to alter
afferent arteriolar resistance while decreasing efferent resis-
tance and augmenting the glomerular ultrafiltration coefficient
(LpA) of remnant kidneys [271; proteinuria remained un-
changed. This small dose was proposed to slow down the
progression of glomeruloscierosis mainly by preventing or
delaying uremic calcinosis [23, 241, while the larger dose used in
our study may have raised glomerular capillary pressures and
thus caused marked and continuous worsening of proteinuria in
the vast majority of our verapamil treated rats. A tendency to
increased proteinuria was also found by Jackson et al [28] six
weeks after subtotal nephrectomy in rats treated with the
calcium channel blocker felodipine.
Proteinuria was significantly correlated to glomeruloscierosis
as well as kidney enlargement at sacrifice, although the causal
relationships between these parameters are not readily appar-
ent. Kidney enlargement could either reflect hypertrophy of
functional renal tissue or could result from storage of material
within growing nonfunctional structures. Kenner et a! [29] in
their comprehensive investigation of morphological alterations
after 5/6 nephrectomy, reported a twofold increase in kidney
weight in rats fed a high protein diet when compared to rats on
a low protein diet. Similarly to our findings, Kenner et al
ascribed the enlargement to "a spongy texture, . . cystic
appearance . . and to marked tubular enlargement . . with the
greatest degree of dilation occurring in proximal and collecting
tubules . . filled with cast material". They suggested these
tubular and interstitial changes to contribute to the progressive
nature of renal failure. In the present study, similarly large
differences in kidney enlargement as well as proteinuria were
obtained in groups of rats with identical diet and equal protein
load but undergoing treatment with different vasoactive drugs.
As noted above, intravenous verapamil acutely increased renal
blood flow and proximal tubular stop flow pressure in our
remnant kidney model despite a fall in systemic arterial blood
pressure [26]. Kidney enlargement might thus reflect tissue
hypertrophy resulting from chronically increased renal perfu-
sion. Such hypertrophy should have involved vascular, glomer-
ular and tubular structures alike. This, however, was not the
case. Although nonsclerotic glomeruli were larger in kidneys
with high proportions of sclerotic glomeruli, there was similar
enlargement in control, in enalapril and in verapamil treated
animals. Hence, glomerular size appeared to be related to the
degree of glomeruloscierosis rather than to the type of treat-
ment. Had a direct pharmacological effect of verapamil been
responsible for the glomerular hypertrophy, one would have
expected larger glomeruli at any level of glomeruloscierosis.
The 10% greater mean glomerular diameter for the verapamil
treated groups can easily be explained by the greater number of
verapamil treated animals with high proportions of sclerosed
glomeruli. Verapamil is unlikely, therefore, to have caused
excessive kidney enlargement directly by chronic hyperperfu-
sion.
A simple explanation for kidney enlargement becomes appar-
ent by observing the whole kidney sections of Figure 3. Not
hypertrophy of viable renal structures but large quantities of
proteinaceous material in dilated tubular areas make up the
difference in size. It is more likely, therefore, that these dilated
tubular structures belong to dying nephrons which are filled and
obstructed by proteinaceous precipitates. Similar morphologi-
cal changes have been observed in adriamycin-induced nephro-
pathy, where massive proteinuria originates from light-micro-
scopically normal-looking glomeruli which develop progressive
sclerosis weeks later associated with increasing kidney weights
[30]. In contrast to the human kidney which shrinks with
progressive renal failure, the rat kidney appears to enlarge due
to precipitation of proteinaceous material in dilating dying
nephrons. This different behavior of rat kidneys may be ex-
plained simply by the much greater amounts of serum proteins
which pass into the tubules of diseased nephrons. In fact,
proteinuria in relation to creatinine excretion or to body weight
rose to levels which were at least five times higher in this
remnant kidney model as compared to humans with the ne-
phrotic syndrome.
The sequence of events which lead to progressive glomeru-
loscierosis has not been clearly established. Hyperfiltration
with increased glomerular capillary pressure [3, 4, 31] as well as
alterations in the mesangial handling of macromolecules [32, 33]
have been recognized as important and probably interrelated
factors [34, 35]. Proteinuria is a marker of disturbed glomerular
capillary function which appears to be characterized not only
by increased leakiness of the glomerular capillary filter but also
by increased macromolecule traffic into the mesangium result-
ing in mesangial injury and glomeruloscierosis [34, 35]. Mesan-
gial uptake and clearance of macromolecules is known to be
altered by angiotensin II both in normal kidneys and in puro-
mycin-induced nephrosis of the rat [34, 35]. The effect of
verapamil on mesangial clearance has not been tested, but it is
conceivable that its vasodilatory effect could increase mesan-
gial uptake of macromolecules similarly to diazoxide [35].
Vasodilators which increase intraglomerular pressures such as
hydralazine in Dahi S rats or in glomerulonephritic spontane-
ously hypertensive rats [36, 37] may accelerate glomeruloscier-
osis by flooding the glomerular mesangium with macromol-
ecules, a mechanism which might explain the deleterious effect
of verapamil in the present study. In contrast, enalapnl could
protect the glomerular mesangium either by reducing intraglo-
merular pressures or by blocking angiotensin 11-dependent
alterations in mesangial macromolecule traffic.
The macromolecular species which are particularly harmful
to the glomerular mesangium appear to be lipoproteins, and
hyperlipidemia has been recognized as an important factor in
progressive glomeruloscierosis [38—40]. The verapamil treated
animals, in contrast to the enalapril groups, tended to have
higher cholesterol levels at sacrifice, probably as a consequence
of their more pronounced proteinuria and hypoalbuminemia.
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Unfortunately plasma lipids were not measured early in the
course of the experiments. Hence, the role of hyperlipidemia or
mesangial uptake of lipoproteins in mediating glomerular injury
cannot be determined in the present study.
In summary, the beneficial effect of converting enzyme
inhibition by enalapnl on progressive glomerulosclerosis in rats
with reduced renal mass was confirmed. Proteinuria and arterial
blood pressure were particularly well controlled by combined
enalapril and salt restriction. The calcium channel blocker
verapamil, administered at a relatively high dose worsened
proteinuria and tended to promote glomerulosclerosis. Further
studies are necessary to conclusively determine whether effec-
tive control of blood pressure by calcium channel blockers
equal to that obtained by enalapril in the present study will also
adversely affect progressive glomerulosclerosis and survival in
rats with renal ablation.
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